# Biotechnology
Latest news and articles about Biotechnology
Total: 46 articles found
Shanghai’s New Blueprint: Inside China’s High-Stakes Push for Brain-Computer Interfaces
Shanghai has released its 15th Five-Year Plan for the service industry, prioritizing breakthroughs in Brain-Computer Interfaces, cell and gene therapy, and AI-driven healthcare. The blueprint aims to integrate cutting-edge biotech with clinical services to address neurodegenerative diseases and demographic shifts.
Illumina’s Genomic Gambit: Standardizing the Search for Cancer’s Ghost Cells
Illumina has launched its first commercial whole-genome sequencing kit for Minimal Residual Disease (MRD) research, aiming to standardize high-sensitivity cancer monitoring. The solution supports both solid and liquid tumors, marking a significant shift from targeted gene panels to comprehensive genomic surveillance in clinical research.
Standardizing the Pulse: China Sets New Benchmarks for Vessel-on-a-Chip Technology
China's market regulator has approved the first national standard for vessel-on-a-chip technology, effective May 2027. This framework establishes technical benchmarks for microfluidic vascular models, aiming to accelerate drug discovery and standardize bio-manufacturing processes across the country.
China’s Oncology Vanguard: Biotech Innovations Take Center Stage at ASCO 2026
Chinese biotech firms and researchers have achieved a record-breaking presence at the 2026 ASCO Annual Meeting, with 95 abstracts selected for major sessions. Led by STAR Market innovators like BeiGene and Biokin, this surge reflects China's transition from a generic-drug manufacturer to a global leader in high-impact oncology research.
Beijing Draws a Line: New Ethical Guardrails for China’s Genomic Ambitions
China's Ministry of Science and Technology has introduced new ethical guidelines to regulate human genetic data research, emphasizing privacy, informed consent, and stratified data protection. The move aims to normalize China's biotech sector and protect sensitive biological assets while aligning with global ethical standards.
Codifying the Code: China Issues New Ethical Framework for Genomic Research
China's Ministry of Science and Technology has introduced new ethical guidelines for human genetic data research, defining the scope of regulated data and emphasizing participant protection. The move aims to standardize the country's biotechnology sector while aligning with national security and data sovereignty objectives.
Protecting the Lab: China Solidifies Drug Data Protection in Historic Regulatory Overhaul
China has implemented a major revision to its drug administration laws, introducing a tiered system that protects clinical trial data for up to six years. This reform aims to incentivize high-end pharmaceutical innovation and align China's intellectual property regime with global standards.
Zhenghai Bio-tech Advances China’s Regenerative Frontier with Stem Cell Milestone
Zhenghai Bio-tech has reached the product validation phase for its human umbilical cord mesenchymal stem cell project. This milestone signifies a major step in the company's shift toward advanced cellular therapy and regenerative medicine.
Governance Shadow Over China’s CRO Giant: Tigermed Founders Targeted by Regulators
The founders of Tigermed, China's leading clinical CRO, are under investigation by the CSRC for disclosure violations regarding past shareholding changes. Despite a massive 1 billion RMB buyback plan to reassure markets, the company faces significant headwinds including a 70% drop in quarterly net profit.
China’s Biotech Coming of Age: Hengrui and BMS Strike Record $15.2 Billion Alliance
Hengrui Pharmaceuticals and Bristol Myers Squibb have signed a landmark $15.2 billion strategic partnership to develop 13 early-stage drug candidates. The deal marks a record for Chinese biotech out-licensing and underscores the growing global reliance on Chinese innovation to replenish pharmaceutical pipelines.
Beyond the Baijiu Benchmark: China's New Tech Guard Challenges Moutai's Margin Supremacy
The 2025 A-share earnings season shows 23 companies surpassing Kweichow Moutai in gross margins, led by innovative biotech and AI firms. This shift highlights China's move toward an IP-driven economy, though many high-margin tech leaders remain in a high-investment, pre-profit phase.
From Bench to Bedside: Isomorphic Labs Targets $2 Billion to Scale AI-Driven Drug Discovery
Isomorphic Labs, a spin-off of Google's DeepMind, is in advanced talks to raise over $2 billion in a funding round led by Thrive Capital. The company aims to leverage its proprietary AI models to revolutionize drug discovery, marking a significant escalation in Big Tech’s expansion into the pharmaceutical sector.